Vivos Therapeutics, Inc.
Financial highlights
| Metric | FY December 31, 2025 | FY December 31, 2024 | FY December 31, 2023 | FY December 31, 2022 | FY December 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $17.4M | $15.0M | $13.8M | $16.0M | $16.9M |
| Gross profit | $10.5M | $9.0M | $8.3M | $10.0M | $12.6M |
| Operating income | -$19.9M | -$11.2M | -$17.3M | -$25.0M | -$20.4M |
| Operating expenses | $30.4M | $20.2M | $25.6M | $35.0M | $33.0M |
| Cost of revenue | $6.9M | $6.0M | $200,000 | $200,000 | $400,000 |
| Cash from operations | -$15.3M | -$12.7M | -$11.9M | -$19.6M | -$15.7M |
| Capital expenditure | $2.3M | $568,000 | $803,000 | $924,000 | $2.4M |
| Free cash flow | -$17.6M | -$13.3M | -$12.7M | -$20.5M | -$18.1M |
| Impairments | — | — | — | — | $911,000 |
| Total assets | $25.2M | $15.3M | $10.7M | $13.7M | $33.7M |
| Total liabilities | $26.7M | $7.3M | $10.3M | $8.9M | $8.2M |
| Total debt | $753,000 | — | — | — | — |
Shares outstanding 13.9M · Free float 89.1%
Annual filing data through FY ended December 31, 2025; float as of June 27, 2026.